Concentrations of nitric oxide in equine preovulatory follicles before and after administration of human chorionic gonadotropin.
In the present study, follicular fluids of estrous mares treated with saline solution (Control) or nitric oxide synthase (NOS) inhibitors were analyzed for nitric oxide (NO), estradiol-17beta (E2) and progesterone (P4) concentrations before and 36h after administration of human chorionic gonadotropin (hCG). Follicular fluids obtained before (0h) hCG administration from control mares had lower concentrations of NO than those obtained 36h after administration of hCG (58.3+/-17.8 micromol versus 340.4+/-57.7 micromol; P<0.05). A similar pattern was also noted for intrafollicular P4 in control mares, which had lower concentrations of intrafollicular P4 before hCG than 36h post-hCG administration (P<0.05). As expected, E2 concentrations of control follicles sampled before hCG administration were higher than those sampled 36h post-hCG administration (P<0.05). However, the E2 concentrations in follicles of mares treated with the NOS inhibitors N(omega)-nitro-L-arginine methyl ester (L-NAME) or aminoguanidine (AG) did not decrease after hCG administration, unlike those in control mares (P>0.10). In addition, mares treated with NOS inhibitors had lower intrafollicular concentrations of NO and P4 than control mares, both before and after hCG administration (P<0.05). Increased intrafollicular concentrations of NO in control, hCG-stimulated mares provide evidence for the presence of an NO-generating system in the equine preovulatory follicle that is likely upregulated following administration of hCG.
Pinto
C R F
CR
Equine Health Studies Program, Department of Comparative Biomedical Sciences, Louisiana State University and Agricultural Center, Baton Rouge, LA 70803, USA. carlos_pinto@ncsu.edu
Paccamonti
D L
DL
Eilts
B E
BE
Venugopal
C S
CS
Short
C R
CR
Gentry
L R
LR
Thompson
D L
DL
Godke
R A
RA
D000818:Animals; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000032:analysis; D005260:Female; D015571:Follicular Fluid / Q000737:chemistry*; D006146:Guanidines / Q000494:pharmacology; D006736:Horses / Q000378:metabolism*; D007700:Kinetics; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000032:analysis*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D010060:Ovulation; D011374:Progesterone / Q000032:analysis
D006063:Chorionic Gonadotropin; D004791:Enzyme Inhibitors; D006146:Guanidines; D009569:Nitric Oxide; D011374:Progesterone; D004958:Estradiol; D019001:Nitric Oxide Synthase; C004479:pimagedine; D019331:NG-Nitroarginine Methyl Ester